Clinical Observation of Xiaoaiping Injection with Rectum Administration Combined Conventional Chemo-therapy in the Treatment of Epithelial Ovarian Tumor
10.6039/j.issn.1001-0408.2015.20.28
- VernacularTitle:消癌平注射液直肠给药联合常规化疗治疗上皮性卵巢癌的临床观察
- Author:
Aiying SONG
;
Fengxia LI
;
Yin TANG
;
Xiangni ZOU
- Publication Type:Journal Article
- Keywords:
Xiaoaiping injection;
Rectum administration;
Combined chemotherapy;
Epithelial ovarian tumor
- From:
China Pharmacy
2015;(20):2815-2817
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe clinical efficacy and safety of Xiaoaiping injection with rectum administration combined with conventional chemotherapy in the treatment of epithelial ovarian tumor. METHODS:60 patients diagnosed as epithelial ovari-an tumor were divided into observation group and control group according to the actual order,with 30 cases in each group. AU pa-tients received TC chemotherapy,4-6 cycles in total;And patients in control group received TC chemotherapy for 3 weeks,i.e. pa-clitaxel 175 mg/m2,3 h,i.v.+carboplatin AUC=5-7.5,1 h,i.v.. Based on this,observation group was additionally given Xiaoaip-ing injection with rectum administration,20-30 ml each time,once a day,2 weeks as a treatment course. Clinical effective rate, 1-year progression-free survival rate and median progression free survival and the incidence of adverse events were compared be-tween 2 groups. RESULTS:Effective rate of observation group was 83.33%,and higher than that of control group (53.33%);there was statistically significant difference (χ2=13.20,P<0.05);1-year progression-free survival rate of observation group was 86.67%,and median progression free survival was 11.3 months;those of control group were 63.33% and 7.2 months;there was statistically significant difference between 2 groups (P<0.01 or P<0.05). There was no significant difference in the incidence of ADR between 2 groups(χ2=0.53,P=0.47). CONCLUSIONS:Xiaoaiping injection with rectum administration combined with con-ventional chemotherapy in the treatment of epithelial ovarian cancer show good curative effect and safety,high 1-year progres-sion-free survival rate and long median progression-free survival.
